This page shows the latest SGLT-2 news and features for those working in and with pharma, biotech and healthcare.
drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,
The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose
PIONEER 4 saw the enrolment of 711 people with type 2 diabetes inadequately controlled on metformin, or without an SGLT-2 inhibitor. ... Patients achieved a 4.7 and 5.0kg loss compared to 3.2 and 3.1kg with Victoza and 0.7 and 1.2kg with placebo.
The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.". ... Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in
The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a
Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients. . ... It is the first time that any diabetes treatment has been approved with a cardiovascular claim and - according to Evercore analyst John Scotti – this could boost
More from news
Approximately 7 fully matching, plus 27 partially matching documents found.
This is the first large real-world evidence study of its kind, evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type 2 diabetes ... receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s
2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2 CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 2, 075. Lexicon Pharmaceuticals. Sanofi.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...